Introduction
Intra-amniotic inflammation in both preterm labor patients with intact membranes and in prelabor rupture of membranes is often subclinical in nature (1) (2) (3) . However, this process can lead to a systemic maternal inflammatory response that is known as clinical chorioamnionitis (4) . Clinical chorioamnionitis is the most common infection-related condition diagnosed in labor and delivery units around the world. It is most frequent in young primiparous women and is estimated to have affected nearly 38,000 live births in the United States alone in 2014 (5, 6) . In addition to intense maternal inflammatory response, intra-amniotic infection elicits an acute histologic chorioamnionitis (7) and frequently, a fetal inflammatory response, which is manifested as funisitis or chorionic vasculitis (8) (9) (10) (11) .
Clinical chorioamnionitis and puerperal endomyometritis are the leading causes of infection related complications in pregnant women. In addition to the maternal morbidity associated with clinical chorioamnionitis and puerperal infections, neonates born to mothers with clinical chorioamnionitis at term are at increased risk for long-term complications, notably cerebral palsy (11) (12) (13) .
The features of clinical chorioamnionitis include maternal fever, maternal or fetal tachycardia, leukocytosis, uterine tenderness, and foul-smelling amniotic fluid (14) (15) (16) . We recently reported that clinical chorioamnionitis at term is a heterogeneous condition, as only 54% of patients have intraamniotic infection (also called microbial-associated intra-amniotic inflammation), 24% have intraamniotic inflammation without detectable microorganisms (sterile intra-amniotic inflammation), and 22% administration of these agents is unnecessary for those without intra-amniotic inflammation/infection.
Identification of biomarkers to delineate clinical chorioamnionitis in the presence and absence of intraamniotic infection would significantly advance our understanding of the disease as well as meet our diagnostic needs.
Bioactive lipids derived from the metabolism of polyunsaturated fatty acids (PUFA) such as arachidonic acid act as mediators in the inflammatory response to injury caused by both microorganisms (bacterial or viral) and cellular damage (sterile) (20) (21) (22) (23) . These lipids also ensure resolution of inflammation (21, 22) . Prostaglandins play an important role in parturition at term (24) (25) (26) and it is possible that an increase in amniotic fluid inflammatory lipids such as prostaglandin E 2 (PGE 2 ), leukotriene B 4 (LTB 4 ), etc., in clinical chorioamnionitis can be observed. In fact, amniotic fluid concentrations of LTB 4 (as well as other 5-lipoxygenase derived metabolites of arachidonic acid) are significantly higher in patients with clinical chorioamnionitis and microbial-associated intra-amniotic inflammation than in those with sterile intra-amniotic inflammation (27) . Recent evidence suggests that, in the normal course of events, a typical inflammatory response is followed by the synthesis of proresolution mediators such as lipoxins, resolvins, and protectins from PUFA to inhibit further leukocyte infiltration (20, 21) . Biosynthesis of these resolution mediators is facilitated by the same polymorphonuclear leukocytes that generate inflammatory lipid mediators, following an acute inflammatory response (28-30). Such lipid mediator class switching is crucial to limit inflammation to a homeostatic function and prevent a chronic inflammatory response (28). As an acute inflammatory condition, clinical chorioamnionitis at term is expected to elicit an amniotic fluid lipid mediator profile distinct from that of spontaneous labor at term. Therefore, the bioactive lipid profiles of amniotic fluid in clinical chorioamnionitis at term may reflect an imbalance between pro-and anti-inflammatory lipid mediators in favor of the pro-inflammatory state, when compared to spontaneous labor.
To test this hypothesis, the amniotic fluid fatty acyl lipidome of patients at term in spontaneous labor with or without clinical chorioamnionitis was analyzed, utilizing an unbiased liquid 
Sample collection:
Amniotic fluid samples were obtained by transabdominal amniocentesis performed for evaluation of the microbial and inflammatory status of the amniotic cavity in patients presenting with clinical chorioamnionitis at term, whereas patients approaching term underwent an amniocentesis for assessment of fetal lung maturity. This information was used by obstetricians and neonatologists in the management of mothers and neonates in terms of treatment with antibiotics. Women at term in labor consisted of those who were admitted for suspected preterm labor because of uncertain dates and had an amniocentesis for the assessment of fetal lung maturity. The criteria for considering whether these patients were at term in labor were derived retrospectively, and were: 1) spontaneous labor; 2) delivery within 24 hours of amniocentesis; 3) analysis of amniotic fluid consistent with fetal lung maturity; 4) birth weight >2500 grams; 5) absence of respiratory distress syndrome or other complications of prematurity; and 6) physical examination of the newborn by a pediatrician that was consistent with a term neonate. Samples of amniotic fluid were transported to the laboratory in a sterile capped syringe and cultured for aerobic/anaerobic bacteria and genital Mycoplasmas. White blood cell (WBC) count (35) , glucose concentration (36) and Gram stain (37) were also performed shortly after collection, as previously described. The results of these tests were used for clinical management. Results of IL-6 concentrations in amniotic fluid were used only for research purposes. Amniotic fluid not required for clinical assessment was centrifuged at 1300 x g for 10 min at 4°C and the supernatant was stored at −70°C.
Detection of Microorganisms with Molecular Methods:
In addition to standard cultivation techniques, the amniotic fluid of patients with clinical chorioamnionitis was analyzed using broad-range real-time polymerase chain reaction with electrospray ionization mass spectrometry (PCR/ESI-MS) (Ibis®Technology -Athogen, Carlsbad, CA, USA), as previously described (34) . Briefly, DNA was extracted from 300µL of amniotic fluid using a method that combines bead-beating cell lysis with a magnetic-bead-based extraction method (38, 39). The extracted DNA was amplified by the previously described broad bacteria and candida (BAC) detection assay, according to the manufacturer's instructions. PCR/ESI-MS can identify 3400 bacteria and 40 Candida spp., which are represented in the platform's signature database (40).
After PCR amplification, 30µL aliquots of each PCR product were desalted and analyzed via electrospray ionization mass spectrometry (ESI-MS). The presence of microorganisms was determined by signal processing and triangulation analysis of all base composition signatures obtained from each sample and compared to a database. The sensitivity (lower limit of detection -LOD) of the assay for the detection of bacteria in blood is, on average, 100 colony-forming unit (CFU)/mL (95% CI, 6-600 CFU/mL). A comparison of detection limits between blood and amniotic fluid shows that the assays have comparable detection limits (100 CFU/mL).
Determination of IL-6 concentrations in amniotic fluid:
Concentrations of IL-6 in amniotic fluid were determined by sensitive and specific enzyme immunoassays obtained from R&D Systems (Minneapolis, MN). The initial assay validation was performed in our laboratory prior to the conduction of this study. The concentrations were determined by interpolation from the standard curves. The inter-and intra-assay coefficients of variation for IL-6 were 8.7% and 4.6%, respectively. The sensitivity of the assay for IL-6 was 0.09 pg/mL.
Sample preparation and LC-MS analysis:
Fatty acyl lipids from amniotic fluid samples were extracted and analyzed by LC-MS, as described earlier (26). However, the LC-MS analysis included Multiple Reaction Monitoring (MRM) of metabolites of linoleic, eicosapentaenoic, and docosahexaenoic acids in addition to arachidonic acid. A complete list of the analyzed PUFA metabolites, the internal standards used, mass spectrometric conditions, as well as the detection limits of individual lipid mediators were presented in Supplementary Data, Table S1 . Under standardized conditions, the detection limits of most eicosanoids are ca. 2 pg on the column and the limit of quantitation was 5 pg at a signal/noise ratio of 3. Since the sample volume used was 200 µL, this translates to an assay sensitivity of 0.03 nM for an average molecular mass of 330 of the detected eicosanoids.
Statistical Analysis:
For any detectable lipid analyte in a subject group, a zero value observed in any sample was replaced with half the average detection limit of the LC-MS method used for the eicosanoids (i.e. 0.015 nM). This ensures that information from all samples was used in the statistical analysis and that the fold change between groups was finite for each analyte. A Wilcoxon test, which does not rely on any distributional assumptions about the data, was used for all pair-wise group comparisons. The significance of p value from the Wilcoxon test is independent on the choice of the threshold concentration used to replace the values below the quantitation limits of the assay.
A parametric alternative to the Wilcoxon test was also applied by using a t-test for analytes with concentrations above the quantitation limits of the assay in all samples, or using censored regression otherwise. In the presence of a perfect separation between groups, the maximum likelihood estimation involved in censored regression could not be applied, and hence a t-test was used instead.
To account for multiple testing, the p value obtained for all analytes in a given group comparison was adjusted to control the False Discovery Rate (FDR) (41). A threshold of 10% on the FDR was used to infer significance.
All analyses were performed under the R statistical language and environment, version 3.0 (www.r-project.org), using the censReg R package for the censored regression analysis (42).
Results

Clinical characteristics of the study population:
The demographic and clinical characteristics of patients are described in Table 1 . The patient groups include women at term gestation with spontaneous labor (TLB, n=35) and those with clinical chorioamnionitis at term (TCC, n=24). Patients with clinical chorioamnionitis at term were further subdivided into: 1) those with MIAC (TCC-MIAC, n=12); and 2) those without MIAC (TCC-noMIAC, n=12). IL-6 concentrations in amniotic fluid were greater in the TCC-MIAC group than in the TCCnoMIAC group, however, the statistical significance was marginal (p = 0.07). The TLB group had, yet, lower IL-6 concentrations than the TCC-noMIAC group.
LC-MS analysis of amniotic fluid fatty acyl lipidome:
The LC-MS method included MRM transitions to encompass stable metabolites of linoleic acid, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid produced by cyclooxygenase, lipoxygenase, and the epoxygenase pathways of PUFA metabolism (details of the metabolites analyzed and the standard abbreviations are provided in Supplementary data - Table S1 ). Each detected fatty acyl Table S2 ). Only the lipid mediators that showed significant differences between TLB and TCC-noMIAC with p < 0.005 were included in the figures. Table 2 ). These similarities were also evident when the median concentrations of primary prostaglandins (PGE 2 and PGF 2 a) and their corresponding downstream metabolites (15-keto PGE 2 , PGA 2 , 13,14-dihydro-15-keto PGE 2 (measured as bicyclo PGE 2 ) from PGE 2 and 15-keto PGF 2 a, 13,14-dihydro-15-keto PGF 2 a from PGF 2 a) were summed to assess their aggregate biosynthesis (Supplementary Data, Table S3 ). Despite higher concentrations in TCC-MIAC and lower concentrations in TCC-noMIAC groups compared to the TLB group, there was no statistically significant difference in the median concentrations of the cyclooxygenase-derived eicosanoids between any of the patient groups. The exception was 13,14-dihydro-15-keto PGF 2 α, which was higher in TCC-MIAC than in the TLB group (Table 2) .
MIAC (TCC-MIAC) and without MIAC (TCC-noMIAC) (
Lipoxygenase pathway metabolites:
Hydroxy fatty acids derived from both w-6 and w-3 PUFA in the lipoxygenase pathway were detectable in all three patient groups (Table 3 ). There were no significant differences between spontaneous labor at term (TLB) and clinical chorioamnionitis with detectable microorganisms in the amniotic cavity (TCC-MIAC) with respect to the median concentrations of the hydroxy fatty acids from either w-6 or w-3 PUFA, except for 12-HETE, 15-HETE, and 11-HEPE, which are higher in TCC-MIAC than in the TLB group (Table 3) . On the other hand, virtually all hydroxy fatty acids derived from w-3 PUFA were significantly lower in patients with clinical chorioamnionitis without detectable microorganisms in the amniotic cavity (TCC-noMIAC) than in those with TLB (Table 3 , Figures 1 and   2 ). While 5 of 9 hydroxy fatty acids from w-6 PUFA (Table 3) were also lower in patients with TCCnoMIAC than in those with TLB, the difference in concentration was more pronounced in w-3 PUFAderived hydroxy fatty acids (HOTrEs, HEPEs, and HDoHEs, 5 fold lower in TCC-noMIAC than TLB) than w-6 PUFA-derived hydroxy fatty acids (HOTrE-g, HEDE, and HETEs, 2 fold lower in TCCnoMIAC than TLB) (Supplementary Data, Table S2 ).
Epoxygenase pathway metabolites:
The concentration of epoxy fatty acids derived from the metabolism of PUFA in the epoxygenase pathway, especially from w-3 PUFA (EpETEs and EpDPEs), were significantly lower in patients with clinical chorioamnionitis at term, regardless of the status of MIAC (TCC-noMIAC and TCC-MIAC) than in spontaneous labor at term (TLB) (p <10 -7 to 10 -3 ) ( Table 4 , Figures 3 and 4) . Alternatively, the epoxy fatty acids derived from the epoxygenase metabolism of w-6 PUFA (EpOMEs and EpETrEs) were only lower in patients with clinical chorioamnionitis without MIAC (TCC-noMIAC, p < 10 -7 to 10 -4 ), but not in those with TCC-MIAC, (p = 0.1 to 0.97) than in those with TLB (Table 4 , Figure 3 ). Vicinyl dihydroxy PUFA resulting from the hydrolysis of these epoxy fatty acids were also included in the analysis (Supplementary Data, Table S1 ) but were not detectable in any of these samples (data not shown). The median IL-6 concentrations in amniotic fluid of patients with clinical chorioamnionitis at term are significantly higher than in those with spontaneous labor at term (TLB) ( (Table 4 and Supplementary Data, Table S2 ). However, the concentration of epoxygenase pathway metabolites of PUFA, especially those derived from w-3 PUFA, were significantly lower in the amniotic fluid of patients with clinical chorioamnionitis, regardless of the presence/absence of bacteria in the amniotic fluid, than in those with spontaneous labor at term (TLB) ( Table 4 , Figures 3 and 4) . As can be expected, not all epoxy PUFA concentrations were lower (in relation to prostaglandins) to the same extent (Table 4 , and Supplementary Data, Table S3 ). While 8(9)-EpETE is undetectable in both clinical chorioamnionitis groups and 17(18)-EpETE was not detectable in TCC-no MIAC, the rest of the epoxy PUFA were lower to varying degrees ( Table 4 Although little is known about the role of epoxy PUFA in reproductive biology, studies in cardiovascular and renal physiology showed that epoxy PUFA are anti-inflammatory by inhibition of cytokine-mediated activation of NF-κB as well as their analgesic, antihypertensive, and antifibrotic activities (62) (63) (64) . It is likely that the anti-inflammatory activities of epoxy PUFA provide a balance to the pro-inflammatory properties of prostaglandins (e.g. PGE 2 ) in human amniotic fluid during spontaneous labor at term as a normal physiological response. Thus, the ratio of prostaglandins to the epoxy PUFA in spontaneous labor at term (TLB) likely signifies a homeostatic response in a normal physiological event.
Any significant change in this ratio in favor of prostaglandins, either by an increase in prostaglandins or by a decrease in epoxy PUFA, could result in an inflammatory condition. Indeed, the ratios of both PGE 2 and PGF 2 a (as well as the sums of the metabolites of each of these prostaglandins) tilted 50-100% in favor of prostaglandins, primarily due to decreased concentrations of epoxy PUFA (Supplementary Data, Table S3 ). This suggests an intriguing possibility that a loss of balance between pro-and anti-inflammatory lipid mediators in clinical chorioamnionitis at term, represented by cyclooxygenase and epoxygenase metabolites, respectively, manifests in sterile intra-amniotic inflammation. This inflammatory response is further exacerbated by a failure of pro-resolution mediator biosynthesis as suggested by lower concentrations of hydroxy w-3 PUFA, the precursors of SPMs (vide supra).
Furthermore, it can be surmised that physiological responses such as fever and tachycardia that are mediated by prostaglandins, are held in abeyance during spontaneous labor at term by the antipyretic, analgesic, and anti-inflammatory actions of the epoxygenase and lipoxygenase derived lipid mediators.
This represents a novel concept that clinical chorioamnionitis, in the absence of microbial invasion of the amniotic cavity, is a result of failed endogenous anti-inflammatory lipid mediator biosynthesis in an ordered and latent 'inflammatory' physiological process, i.e. parturition. 5.32x10 -4 0.18 0.22
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